Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott
Clinical Therapeutics (2015) Vol. 37, Iss. 4, pp. 764-782
Open Access | Times Cited: 533

Showing 1-25 of 533 citing articles:

Skin microbiota–host interactions
Y. Erin Chen, Michael A. Fischbach, Yasmine Belkaid
Nature (2018) Vol. 553, Iss. 7689, pp. 427-436
Open Access | Times Cited: 601
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 12, pp. 3158-3167
Open Access | Times Cited: 520
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak, Radosław Kitel, Sara Przetocka, et al.
Structure (2015) Vol. 23, Iss. 12, pp. 2341-2348
Open Access | Times Cited: 471
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
Susanne Steggerda, Mark K. Bennett, Jason Chen, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 357
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 339
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Simon Tiberi, Nelita du Plessis, Gerhard Walzl, et al.
The Lancet Infectious Diseases (2018) Vol. 18, Iss. 7, pp. e183-e198
Open Access | Times Cited: 329
Mechanisms regulating T-cell infiltration and activity in solid tumors
Evripidis Lanitis, Denarda Dangaj, Melita Irving, et al.
Annals of Oncology (2017) Vol. 28, pp. xii18-xii32
Open Access | Times Cited: 326
T cell receptor (TCR) signaling in health and disease
Kinjal Shah, Amr Al‐Haidari, Jianmin Sun, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 317
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea‐Yea Huang, Ariel Francois, A. J. Robert McGray, et al.
OncoImmunology (2016) Vol. 6, Iss. 1, pp. e1249561-e1249561
Open Access | Times Cited: 309
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander T. Faje
Pituitary (2015) Vol. 19, Iss. 1, pp. 82-92
Closed Access | Times Cited: 289
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu, Jinghe Lang
Oncotarget (2017) Vol. 8, Iss. 57, pp. 97671-97682
Open Access | Times Cited: 278
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol, Michael A. Postow, Marianne Davies, et al.
Cancer Treatment Reviews (2017) Vol. 58, pp. 70-76
Open Access | Times Cited: 266
Intratumor and Intertumor Heterogeneity in Melanoma
Tomasz M. Grzywa, Wiktor Paskal, Paweł Włodarski
Translational Oncology (2017) Vol. 10, Iss. 6, pp. 956-975
Open Access | Times Cited: 260
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista, Luı́s Otávio Sarian, Sophie Derchain, et al.
Human Pathology (2015) Vol. 47, Iss. 1, pp. 78-84
Closed Access | Times Cited: 226
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, et al.
ESMO Open (2017) Vol. 2, Iss. 4, pp. e000247-e000247
Open Access | Times Cited: 226
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Massimo Ralli, Andrea Botticelli, Irene Claudia Visconti, et al.
Journal of Immunology Research (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 197
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Daniel L. Suzman, Lorraine Pelosof, Amy S. Rosenberg, et al.
Liver International (2018) Vol. 38, Iss. 6, pp. 976-987
Open Access | Times Cited: 194
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Masatoshi Kudo
Oncology (2017) Vol. 92, Iss. Suppl. 1, pp. 50-62
Open Access | Times Cited: 182
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
Elena Gianchecchi, Alessandra Fierabracci
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 180
Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences
Nikko Brix, Anna Tiefenthaller, Heike Anders, et al.
Immunological Reviews (2017) Vol. 280, Iss. 1, pp. 249-279
Open Access | Times Cited: 171
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
Subrata Chowdhury, Joe Veyhl, Fatima Jessa, et al.
Oncotarget (2016) Vol. 7, Iss. 22, pp. 32318-32328
Open Access | Times Cited: 170
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195
Qingming Wang, Guang‐Yu Lian, Yuan Song, et al.
Life Sciences (2019) Vol. 231, pp. 116335-116335
Closed Access | Times Cited: 169
Mass Cytometry Imaging for the Study of Human Diseases—Applications and Data Analysis Strategies
Heeva Baharlou, Nicolas Canete, Anthony L. Cunningham, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 169
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 949-982
Open Access | Times Cited: 168
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Soumaya Kouidhi, Farhat Ben Ayed, Amel Benammar Elgaaïed
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 166
Page 1 - Next Page

Scroll to top